Talc: FDA Review, IARC Reclassification & Regulatory Intelligence

What Is Talc?

Talc is a naturally occurring mineral composed of hydrated magnesium silicate, with the chemical formula Mg₃Si₄O₁₀(OH)₂. It is the softest known mineral, rated 1 on the Mohs hardness scale, and is prized across industries for its ability to absorb moisture, reduce friction, prevent caking, and create a smooth, opaque finish. It appears as a white to grayish-white powder that is odorless and chemically inert under normal conditions.

Property	Value
Chemical Name	Hydrated magnesium silicate
Molecular Formula	Mg₃Si₄O₁₀(OH)₂
CAS Number	14807-96-6
UNII	7SEV7J4R1U
Mohs Hardness	1 (softest mineral)

The mineral forms in metamorphic rocks through the alteration of magnesium-rich minerals such as olivine, pyroxene, and amphibole. Major global deposits are found in China, South Korea, India, Brazil, France, Italy, and the United States (primarily Montana and Vermont). The geological conditions under which talc forms are critical to its safety profile: talc deposits may occur in proximity to asbestos-bearing minerals, particularly tremolite, anthophyllite, and chrysotile. This co-occurrence is the root of the contamination risk that has driven decades of regulatory scrutiny.

Three grades of talc are commercially relevant:

• Food-grade talc — used as an anticaking agent, processing aid, and release agent in products including chewing gum, rice, table salt, and confectionery
• Pharmaceutical-grade talc — serves as an excipient in tablet and capsule manufacturing, functioning as a glidant, lubricant, and diluent. Must conform to USP monograph specifications.
• Cosmetic-grade talc — used in body powders, face powders, eye shadows, blushes, foundations, and deodorants

FDA Regulatory Status

Talc's FDA regulatory status is fragmented across multiple frameworks, reflecting its use in food, drugs, and cosmetics.

Food Use

Talc is listed as Generally Recognized as Safe (GRAS) under 21 CFR 182.70 for substances migrating from cotton and cotton fabrics used in dry food packaging, and under 21 CFR 182.90 for substances migrating to food from paper and paperboard products. It is also approved as an indirect food additive under 21 CFR 176.170 and 21 CFR 178.3297.

In practice, talc is used as a direct food additive — as an anticaking agent in table salt, a polishing agent on rice and confectionery, and a processing aid in chewing gum. FDA Commissioner Martin Makary stated in May 2025 that an estimated 20 million Americans consume talc regularly as a food and drug additive.

Drug Use

Talc is approved as a color additive for drugs under 21 CFR 73.1550 and for externally applied cosmetics under 21 CFR 73.2500. As an inactive ingredient (excipient), talc remains widely used in pharmaceutical manufacturing — it appears in four of the ten most commonly prescribed medications in the United States, according to FDA's 2025 expert panel proceedings.

Cosmetic Use

Talc has no specific FDA pre-market approval requirement for cosmetic use. Under MoCRA (Modernization of Cosmetics Regulation Act of 2022), cosmetics must not be adulterated — meaning they must not contain a poisonous or deleterious substance. However, there is no FDA regulation setting a maximum level for asbestos in talc-containing cosmetics, nor is there a current federally mandated testing method.

FDA Expert Panel (May 2025)

On May 20, 2025, FDA Commissioner Makary convened the agency's inaugural independent scientific expert panel, choosing talc as the first subject. The panel's findings were notable for their unanimity: all panelists expressed support for removing talc from food and drug products. Panel members highlighted growing evidence that talc is associated with chronic inflammation regardless of asbestos contamination, and noted that safe alternatives exist for virtually all current food and drug applications.

As of March 2026, the FDA has not announced formal rulemaking in response to the panel's findings.

The Proposed Rule and Its Withdrawal

On December 27, 2024, the FDA published a proposed rule on asbestos testing methods for talc-containing cosmetics (89 FR 105490), which would have established the first federally mandated testing methodology.

On November 28, 2025, the FDA officially withdrew the proposed rule (90 FR 54603), citing MAHA priorities, scientific complexity, and legal considerations. The withdrawal was signed by HHS Secretary Robert F. Kennedy Jr. The FDA stated it would issue a new proposed rule, but no timeline has been announced.

Key Deadlines

Date	Event	Type
July 5, 2024	IARC reclassifies talc from Group 2B to Group 2A (probably carcinogenic)	International
September 20, 2024	ECHA RAC classifies talc as Category 1B carcinogen under EU CLP Regulation	International
December 27, 2024	FDA publishes proposed rule on asbestos testing methods for talc cosmetics	Federal
May 20, 2025	FDA Expert Panel — unanimously supports removing talc from food and drugs	Federal
November 28, 2025	FDA withdraws proposed asbestos testing rule	Federal
December 19, 2025	New York Governor signs S.1548 banning talc in menstrual products	State
December 22, 2025	$1.5 billion verdict in Craft v. J&J (Baltimore, mesothelioma)	Legal
December 19, 2026	New York talc ban in menstrual products takes effect	State
~2027	Expected EU ban on talc in cosmetics following CLP 1B classification	International

The Asbestos Contamination Problem

The central regulatory concern with talc is not talc itself — it is the potential presence of asbestos contamination. Talc and asbestos-bearing minerals (particularly tremolite, anthophyllite, and chrysotile) can form in the same geological environments.

In October 2019, the FDA's contract laboratory tested 52 talc-containing cosmetic products and found that 9 of 52 samples (17.3%) tested positive for asbestos contamination. In follow-up testing conducted in 2021, the FDA tested an additional 100 products and found no asbestos. Independent testing by the Environmental Working Group in 2020 found asbestos in nearly 15% of talc-based cosmetics sampled.

The discrepancy highlights a fundamental methodological problem: there is no universally agreed-upon testing protocol for detecting asbestos in talc. Different analytical methods — polarized light microscopy (PLM), transmission electron microscopy (TEM), X-ray diffraction (XRD) — have different sensitivity thresholds and can produce conflicting results on the same sample. This was the exact problem the FDA's withdrawn proposed rule sought to address.

IARC Reclassification (2024)

On July 5, 2024, the International Agency for Research on Cancer published the results of its reassessment as part of IARC Monographs Volume 136. The working group reclassified talc (not containing asbestos or asbestiform fibers) from Group 2B ("possibly carcinogenic") to Group 2A ("probably carcinogenic to humans").

The reclassification was based on:

• Limited evidence for cancer in humans, specifically ovarian cancer associated with perineal use of talc-based body powder
• Sufficient evidence for cancer in experimental animals
• Strong mechanistic evidence that talc exhibits key characteristics of carcinogens

This is distinct from the classification of asbestos-contaminated talc, which has been classified as Group 1 ("carcinogenic to humans") since 1987. The 2024 reclassification applies specifically to talc that does not contain asbestos — meaning the mineral itself, independent of contamination, is now considered probably carcinogenic.

Johnson & Johnson Litigation

The talc litigation against Johnson & Johnson is the largest mass tort in the substance's history. As of March 2026, approximately 67,000 claims are pending in the multidistrict litigation (MDL) in the U.S. District Court for the District of New Jersey.

Key Timeline

• May 2020: J&J discontinued talc-based Baby Powder in the United States and Canada
• August 2022: J&J announced global transition to cornstarch-based formulations
• 2023: Talc-based Baby Powder discontinued worldwide
• April 2025: Federal judge rejected J&J's third bankruptcy attempt (the "Texas Two-Step" strategy via Red River Talc), which included an ~$8 billion settlement proposal
• December 22, 2025: Baltimore City jury returned a $1.5 billion verdict in Craft v. J&J (peritoneal mesothelioma), including ~$59.8 million in compensatory and the remainder in punitive damages

The litigation discovery process has produced internal industry documents that informed FDA's testing programs and the MoCRA-authorized rulemaking effort.

International Status

European Union

On September 26, 2024, ECHA's Committee for Risk Assessment (RAC) classified talc as a Category 1B carcinogen ("presumed to have carcinogenic potential") under the CLP Regulation. Under Article 15 of the EU Cosmetics Regulation (EC No 1223/2009), substances classified as CMR Category 1A or 1B are automatically prohibited in cosmetic products unless a specific exemption is granted. A ban on talc in EU cosmetics is expected by approximately 2027.

Currently, talc is restricted in the EU: powdery cosmetic products for children under 3 must carry the warning "Keep powder away from children's nose and mouth."

United Kingdom

The UK HSE published a technical report in January 2026 that does not support a carcinogenicity classification for talc, diverging from the EU RAC position. This creates a potential regulatory split between UK and EU markets.

Canada

Health Canada's screening assessment concluded talc enters the environment in conditions that may constitute a danger to human life or health. Canada is considering measures to reduce perineal and inhalation exposures. Asbestos above trace levels is prohibited under CEPA regulations.

Other Jurisdictions

• ASEAN: Advisory statement issued; monitoring new data, requires inhalation warnings for children's products
• Japan: Permitted in cosmetics with strict purity standards; monitoring international developments

Affected Product Categories

Cosmetics

• Body powders and baby powders (most affected — most major brands have already reformulated)
• Face powders, foundations, setting powders
• Eye shadows, blushes, bronzers
• Deodorants and antiperspirants

Pharmaceuticals

• Tablet and capsule excipients (glidant, lubricant, diluent, coating agent)
• Four of the ten most commonly prescribed US medications contain talc

Food Products

• Table salt (anticaking agent)
• Rice and confectionery (polishing agent)
• Chewing gum (release agent)
• Candy marketed to children
• Milk and cream powders, cheese, breakfast cereals

Dietary Supplements

• Tablet manufacturing (glidant, anticaking)
• May appear on labels as "magnesium silicate"

Menstrual Products

• Tampons, pads, menstrual cups, period underwear
• Subject to New York S.1548 ban effective December 2026

What Companies Should Do

Immediate (Q1-Q2 2026)

1. Audit current talc usage across all product lines. Identify every product containing talc, the grade used (food, pharmaceutical, cosmetic), the supplier, and the intended market.

2. Assess supplier testing protocols. In the absence of a federal testing standard, request documentation of your suppliers' testing methods, detection limits, and chain-of-custody controls for talc sourcing.

3. Comply with New York menstrual product ban. If you sell menstrual products in New York, reformulation must be complete before December 19, 2026. Begin formulation work now.

4. Prepare for EU cosmetics ban. If you sell cosmetics in the EU, begin evaluating talc alternatives. The timeline for the ban under Article 15 is approximately 2027.

Medium-Term (Q3-Q4 2026)

5. Develop reformulation plans for food and drug applications. The FDA expert panel's unanimous recommendation to remove talc from food and drugs has not yet resulted in rulemaking, but the direction is clear. Alternatives include cornstarch, rice starch, silicon dioxide, calcium silicate, and microcrystalline cellulose.

6. Track state-level legislative activity. New York's menstrual product ban may be followed by similar legislation in other states.

7. Document your risk assessment. Whether or not you reformulate, maintain documentation reflecting current scientific evidence (IARC Group 2A, ECHA RAC 1B), your testing protocols, and the basis for your decisions.

Ongoing

8. Watch for the replacement proposed rule. The FDA stated it will issue a new proposed rule on asbestos testing to meet MoCRA Section 3505 obligations.

9. Track GRAS reform developments. The FDA's 2026 proposed regulation on GRAS notices could affect the regulatory basis for talc in food.

10. Maintain litigation awareness. With ~67,000 pending claims and recent $1.5B verdicts, the litigation landscape continues to shape regulatory momentum.

Regulatory Intelligence

Policy Canary tracks regulatory developments affecting talc across FDA, USDA, international bodies, and state legislatures. Subscribe to receive alerts when new regulatory actions affect this substance.